Clinical Trial Update

Provectus has received Orphan Drug Designations from the FDA for the treatment of metastatic melanoma and hepatocellular carcinoma.

Read More

Leading the Way

Provectus is investigating new treatments for oncology and dermatology.

Contact Us

Provectus Biopharmaceuticals, Inc. does not endorse nor is responsible for the content in any links provided to websites not maintained by Provectus Biopharmaceuticals, Inc. These links are provided merely for the user's convenience. Occasionally, Provectus Biopharmaceuticals, Inc. may provide information related to medical conditions or their treatment on this website. This information is not meant to be a substitution for consultation with proper medical professionals. You should always consult a physician or medical advisor.